Diarrhea News and Research

Latest Diarrhea News and Research

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

Innovation Fund Denmark supports research project that aims to fight Clostridium difficile diarrhea

One man's trash is another man's treasure, as the saying goes. If things go to plan, feces from registered and thoroughly tested healthy donors will in a few years be the standard treatment for the bacterium Clostridium difficile at Danish hospitals.

21 Sep 2018

Insulin treatment shows great potential against chronic bowel inflammation

Millions of people take insulin every day to treat their diabetes. But diabetes is not the only disease on which insulin has an effect, it appears.

21 Sep 2018

$CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL$

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for VENCLYXTO® in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who have received at least one prior therapy.

21 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Novel treatment for hairy cell leukemia approved by FDA

The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Bacteria in the gut found to produce electricity

Researchers have discovered hundreds of bacterial species, including those in the human gut, that can generate electricity.

13 Sep 2018

New insight on mechanics of rotavirus could open up avenues for effective treatments

Researchers have provided new insight on the mechanics of a virus that causes severe diarrhea and sickness in young children, according to a report published in eLife.

12 Sep 2018

New paper reports conserved collateral susceptibility to antibiotics in E. coli

LSTM's Dr Adam Roberts is a co-author on a new paper published in Nature Communications which reports conserved collateral susceptibility to antibiotics in the human pathogen Escherichia coli.

10 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Fiber strengthens intestinal barrier and counteracts gastrointestinal problems

Similar to patients with Crohn's disease, elderly people with stomach problems have a intestinal barrier that is not functioning optimally.

7 Sep 2018

Cryptosporidiosis worsened by commonly used probiotic

Researchers have found that infection with the intestinal parasite Cryptosporidium parvum is worsened in mice that have been administered a probiotic.

31 Aug 2018

Newborns require special diagnosis and treatment considerations for C. difficile infection

Newborns require special diagnosis and treatment considerations for an infectious diarrhea known as Clostridioides difficile infection, according to a new evidence-based white paper published today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

31 Aug 2018

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

30 Aug 2018

Diarrhea News and Research

Latest Diarrhea News and Research

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Innovation Fund Denmark supports research project that aims to fight Clostridium difficile diarrhea

Insulin treatment shows great potential against chronic bowel inflammation

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

FDA approves new treatment for people with hairy cell leukemia

Novel treatment for hairy cell leukemia approved by FDA

Bacteria in the gut found to produce electricity

New insight on mechanics of rotavirus could open up avenues for effective treatments

New paper reports conserved collateral susceptibility to antibiotics in E. coli

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Fiber strengthens intestinal barrier and counteracts gastrointestinal problems

Cryptosporidiosis worsened by commonly used probiotic

Newborns require special diagnosis and treatment considerations for C. difficile infection

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

E. coli strain in poultry shown to cause bladder infections

E. coli strain found in poultry products may cause bladder infections in people

WVU professor working to predict, prevent a major cholera outbreak in Yemen

Pediatric antibiotic prescriptions lead to nearly 70,000 ER visits in the U.S. each year

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in